Can a targeted drug shrink tumors in patients with specific gene mutations?
NCT ID NCT06630416
First seen Feb 25, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests the drug pemetrexed in people with metastatic bladder cancer or other solid tumors that have certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if the drug can shrink tumors. About 64 adults will take pemetrexed and be monitored for response every 9 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern Medicine Orland Park
RECRUITINGOrland Park, Illinois, 60462, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.